YOLFTbeta
Anti-Microbial Savior BioteQ Co., Ltd.

Anti-Microbial Savior BioteQ Co., Ltd.

6864 · TWO · Healthcare / Biotechnology

37.00TWD-0.40 (-1.07%)

Price History

Full chart

Market Stats

Previous Close37.40
Open38.00
Day Range37.00 – 38.70
52-Week Range39.55 – 87.00
Volume41.48K
Market Cap2.05B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.58
Dividend Yield0.00%
Beta-0.08
50-Day Avg45.51
200-Day Avg56.53

About

Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. The company offers PoroVance precision pore engineering and small-molecule drug discovery. Its pipeline products include FORMOSA-1117, antibacterial drug candidate; YUAN-03, antiviral drug candidate; AMS-2140, broad-spectrum antiviral drug candidate; TenTacle, ADC linker-conjugate compound. Anti-Microbial Savior BioteQ Co., Ltd. was founded in 2018 and is headquartered in Kaohsiung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Zhida Wei
  • Employees33
  • HeadquartersNo. 6, Siwei 3rd Rd., Kaohsiung, Taiwan, 802, Taiwan
  • Websitehttps://www.ams-bioteq.com

Leadership

  • Dr. George TsaiGM & Chairman
  • Dr. Zhida WeiCEO & Director
  • Mr. Yi-Wei ZhangPresident
  • Ms. Li Yu XuHead of Finance & Accounting Supervisor
  • Mr. Nicolas LiuHead of Finance Management Department
  • Mr. Felix TsaiChief Business Officer

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue88.00K2.70M728.00K612.00K706.00K
Growth (%)-+2964.77%-73.01%-15.93%+15.36%
Cost of Revenue41.00K1.41M399.00K468.00K380.00K
Gross Profit47.00K1.29M329.00K144.00K326.00K
Gross Margin53.41%47.91%45.19%23.53%46.18%
Operating Expense28.35M44.66M60.23M76.62M96.31M
Operating Income-28.30M-43.37M-59.91M-76.48M-95.98M
Operating Margin-32164.77%-1608.12%-8228.85%-12496.24%-13595.61%
EBITDA--30.17M-46.24M-63.67M-82.44M
EBITDA Margin--1118.80%-6352.20%-10403.43%-11677.48%
Net Income-22.35M-31.74M-51.78M-74.52M-93.60M
Net Income Margin-25398.86%-1176.75%-7112.91%-12175.98%-13257.37%
R&D21.21M31.63M45.12M53.54M60.93M
R&D as % of Total Revenue24107.95%1172.86%6197.12%8748.37%8630.88%
Interest Expense89.00K82.00K42.00K32.00K21.00K
Interest Expense % of Total Revenue101.14%3.04%5.77%5.23%2.97%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets221.16M181.96M128.05M248.18M520.41M
Total Liabilities17.23M9.77M6.99M10.87M9.92M
Total Equity203.93M172.19M121.05M237.31M510.49M
Cash166.58M131.11M78.43M194.13M466.22M

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-20.13M-30.66M-48.26M-64.15M-77.72M
Capital Expenditure3.29M7.74M1.52M8.37M6.84M
Free Cash Flow-23.41M-38.41M-49.78M-72.52M-84.56M
FCF to OCF116.32%125.25%103.14%113.05%108.80%

Key Statistics & Ratios

Market Cap2.05B
Enterprise Value1.56B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1631.82
Price / Book4.06
EPS-2.58
Book Value12.43
Revenue (TTM)1.26M
Gross Profit (TTM)-344.00K
EBITDA-83.59M
Profit Margin0.00%
Operating Margin-5269.71%
Return on Equity-25.03%
Return on Assets-15.61%
Shares Outstanding37.88M
Shares Float31.18M
Beta-0.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%